摘要
血管内皮细胞生长抑制剂(vascular endothelial growth inhibitor,VEGI)和环状血管内皮细胞生长抑制因子(cyclo-VEGI)均可抑制血管内皮细胞增生及新生血管形成,产生强大抗肿瘤效应。但两者作用机理不同,VEGI诱导内皮细胞凋亡,激活核转录因子NF-κB和维持G0/G1期细胞生长停滞,而cyclo-VEGI抑制血管内皮生长因子(vascular endothelial growth factor,VEGF)和成纤维细胞生长因子-2(fibro-blast growth factor-2,FGF-2)与各自受体结合及VEGF信号转导。将VEGI和cyclo-VEGI应用于以新生血管为靶点的眼部肿瘤治疗中,具有很高的研究价值。本文就其研究现状及应用前景作一综述。
Both vascular endothelial growth inhibitor （VEGI）and cyclopeptidic vascular endothelial growth inhibitor （ cyclo-VEGI ） have powerful marltumor effects by inhibiting the proliferation of endothelial cells and neovascularization. But the mechanisms of them are different： VEGI induces apoptosis of endothelial cells, activates nuclear factor-KB and maintains the growth arrest of endothelial cells in G0 / G1 interfaces; whereas cyclo-VEGI mostly inhibits both the combination of vascular endothelial growth factor,flbroblast growth factor-2 and their receptors, the transduction of vascular endothelial growth factor signals. The application of VEGI and cyclo-VEGI in the treatment of ocular tumors targeting angiogenesis has high applied value, this article reviews the current study and prospects in this field. [ Rec Adv Ophthalmol 2007 ;27（3） ：226-228,232]
出处
《眼科新进展》
CAS
2007年第3期226-228,232,共4页
Recent Advances in Ophthalmology
基金
上海市科委科研基金资助(编号:05nm05010)~~
